Minaris Advanced Therapies in the news
Global Cell Gene Therapy
Tamtam found 20 recent articles about Minaris Advanced Therapies.
- Bionova Scientific and Minaris Announce Partnership to Accelerate Plasmid DNA Supply for Cell and Gene Therapy Manufacturing | Newswise
Bionova Scientific and Minaris announced a strategic partnership to expand access to high-quality plasmid DNA for advanced therapy development and manufacturing.
- Building Commercial Readiness in Advanced Therapies
Eytan Abraham discusses the critical manufacturing decisions and challenges in scaling advanced therapies from development to commercialization for broader patient access.
- Minaris Expands Its Apprentice.io Partnership, Bringing Digital Manufacturing to Its Philadelphia Headquarters
Minaris Advanced Therapies is expanding its digital manufacturing platform partnership with Apprentice.io to its global sites, including its Philadelphia headquarters, to enhance efficiency and collaboration in cell and gene therapy production.
- Minaris Enhances GMP Cell Banking Capabilities at Philadelphia Facility
Upgraded GMP cell banking suites at the Philadelphia facility now offer integrated biosafety testing and expanded manufacturing capacity for cell and gene therapy developers.
- Minaris Enhances GMP Cell Banking Suites at Philadelphia Facility
Minaris upgraded its Philadelphia facility's GMP cell banking suites to provide integrated cell banking and biosafety testing services for cell and gene therapy programs.
- Minaris Fortifies Philly Hub to Streamline Cell & Gene Therapy Production
Minaris enhanced its Philadelphia facility with integrated GMP cell banking and testing suites to streamline cell and gene therapy production.
- Minaris Enhances GMP Cell Banking Suites at Philadelphia Facility
upgraded GMP cell banking suites and integrated testing services at the Philadelphia facility to streamline cell and gene therapy manufacturing.
- Minaris Expands Rapid Mycoplasma Detection Services with bioMérieux's BIOFIRE® Platform to Reduce Turnaround Time for Release and In-Process Testing
Minaris Advanced Testing now offers rapid PCR mycoplasma testing using bioMérieux's BIOFIRE® platform to accelerate lot release and reduce manufacturing timelines for advanced therapies.
- Minaris Expands Rapid Mycoplasma Testing Capabilities to Accelerate Cell and Gene Therapy Manufacturing
Minaris has expanded its rapid mycoplasma testing capabilities by implementing the BIOFIRE® system to accelerate batch release for cell and gene therapy developers.
- Minaris Expands Rapid Mycoplasma Detection Services with bioMérieux's BIOFIRE® Platform to Reduce Turnaround Time for Release and In-Process Testing
Minaris implemented the BIOFIRE platform to accelerate mycoplasma detection and reduce release timelines for cell and gene therapies.
- Minaris Adds BIOFIRE for Faster Mycoplasma Detection
Minaris implemented the BIOFIRE Mycoplasma platform to reduce biosafety testing turnaround times to three days for cell and gene therapy clients.
- Aldevron and Minaris Renew Lentiviral Plasmid Agreement to Accelerate Gene-Modified Cell Therapy Development
Aldevron and Minaris renewed a licensing deal to provide off-the-shelf lentiviral plasmids for faster cell and gene therapy manufacturing.
- Aldevron and Minaris Renew Lentiviral Plasmid Agreement to Accelerate Cell and Gene Therapy Development
Aldevron and Minaris renewed a strategic partnership to supply scalable lentiviral plasmids for cell and gene therapy manufacturing.
- Aldevron and Minaris Renew Lentiviral Plasmid Agreement to Accelerate Gene-Modified Cell Therapy Development
Aldevron and Minaris have extended their partnership to supply off-the-shelf lentiviral plasmids for gene-modified cell therapy manufacturing.
- Aldevron and Minaris Renew Lentiviral Plasmid Agreement to Accelerate Gene-Modified Cell Therapy Development
A renewed partnership between Aldevron and Minaris expands developer access to specialized lentiviral plasmid systems to speed up the manufacturing of gene-modified cell therapies.
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
Minaris successfully manufactured and released all clinical batches for Chimeric Therapeutics' gastrointestinal cancer CAR-T trial during a five-year partnership.
- Minaris Delivers 100% Manufacturing and Release Success for Chim
A five-year partnership with Chimeric Therapeutics has resulted in a 100% manufacturing success rate for a Phase 1 clinical trial targeting gastrointestinal cancers.
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
Minaris successfully manufactured all batches for Chimeric Therapeutics' CDH17 CAR-T program, ensuring consistent clinical supply for its Phase 1A/1B gastrointestinal cancer study.
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
Minaris Advanced Therapies is expanding its cell and gene therapy manufacturing capabilities and leadership.
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
Minaris achieved a perfect success rate in manufacturing clinical batches for Chimeric Therapeutics' gastrointestinal cancer CAR-T trial.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Minaris Advanced Therapies?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies